Group items tagged

As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.

National Library of Medicine National Institutes of Health PubMed Abstract: Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks gestation: a systematic reiew and metaanalysis

NIH, and Eunice Kennedy Shriver National Institute of Child Health and Human Development - Review and trial to determine whether magnesium sulfate administered to women at risk of preterm delivery may reduce the risk of cerebral palsy in their children

Multicenter, randomized, controlled trial to compare the anti-seizure effect of parenteral MgSO4 versus oral labetalol in hypertensive pregnant women who are eligible for MgSO4 therapy. The primary outcome measure is eclampsia, and the secondary outcome measures include blood pressure control, and relevant antenatal, intrapartum, and postnatal maternal and fetal/neonatal parameters including adverse effects and complications.